Swiss generic and biosimilar medicine pharmaceutical company Sandoz announced a series of new interim climate […]
Back to Climate News
ESG Today
Sandoz Unveils New Operational, Supply Chain Climate Goals
Abatify Summary
Nature & Climate Perspective
**Sandoz's commitment to decarbonizing pharmaceutical manufacturing and supply chains reduces industrial pressure on local biodiversity and terrestrial carbon sinks. **
- Decarbonization of manufacturing facilities minimizes localized thermal pollution and chemical emissions, directly supporting regional biodiversity resilience.
- Lowering the carbon intensity of pharmaceutical supply chains reduces the indirect demand for land-intensive industrial expansion, preserving current LULUCF stability.
- The shift toward sustainable procurement models incentivizes raw material suppliers to adopt practices that prioritize environmental stability and ecological health in diverse sourcing regions.
Market & Policy Outlook
**By targeting interim Scope 3 reductions, Sandoz aligns with SBTi-validated pathways and signals a shift toward mandatory corporate transparency and high-integrity market participation. **
- The commitment to rigorous climate goals mirrors the ICVCM Core Carbon Principles (CCPs) by emphasizing real, measurable, and verifiable emission reductions before relying on offset mechanisms.
- Aggressive operational targets drive increased demand for I-RECs and Power Purchase Agreements (PPAs), influencing market pricing and financial liquidity for renewable energy assets.
- Sandoz’s strategic focus on supply chain transparency aligns with global regulatory shifts like the CSRD, forcing a systemic re-evaluation of Scope 3 reporting across the generic pharmaceutical industry.
This story moves you. Here's what you can do.
Related Resources
Sourcing:
Contact our trading desk for customized environmental commodities for your needs
Request sourcing: Article 6.2 (ITMOs)